Indicated for use in the treatment of symptomatic orthostatic hypotension.

A vasopressin/antihypertensive agent.

Forms an active metabolite, desglymidodrine, an alpha1-agonist and exerts its action via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, increasing vascular tone and blood pressure

Can cause marked elevation of supine blood pressure.

Does not stimulate cardiac beta-adrenergic receptors and does affect the CNS.

Standing systolic blood pressure is increased by approximately 15-30 mmHG at 1 hour after a 10 mg dose, and persists for 2-3 hours.

No clinically significant effect on standing or supine pulse rates in patients with autonomic failure.

Trade names Proamatine

A vasopressor/antihypotensive agent.

Approved for the treatment of dysautonomia and orthostatic hypotension.

A prodrug which forms an active metabolite, desglymidodrine.

Desglymidodrine is an α1-receptor agonist and exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature.

Desglymidodrine produces an increase in vascular tone and elevation of blood pressure.

Desglymidodrine does not stimulate cardiac beta-adrenergic receptors.

Desglymidodrine diffuses poorly across the blood–brain barrier, and is therefore not associated with effects on the central nervous system.

After oral administration it is rapidly absorbed.

The plasma levels of the prodrug peak after about half an hour, and decline with a half-life of approximately 25 minutes, while the metabolite reaches peak blood concentrations about 1 to 2 hours after a dose of midodrine and has a half-life of about 3 to 4 hours.

The absolute bioavailability of midodrine measured as desglymidodrine is 93%.

Indicated for the treatment of symptomatic orthostatic hypotension.

Can be used to prevent excessive drops in blood pressure in people requiring dialysis.

Also used in the complications of cirrhosis with octreotide for hepatorenal syndrome causing constriction of splanchnic vessels and dilation of renal vasculature.

Contraindicated in patients with severe organic heart disease, acute renal disease, urinary retention, pheochromocytoma or thyrotoxicosis.

Should not be used in patients with persistent and excessive supine hypertension.

Side effects include: Headache, feeling of pressure/fullness in the head, vasodilation/flushing face, confusion/thinking abnormality, dry mouth; nervousness/anxiety and rash.

Leave a Reply

Your email address will not be published. Required fields are marked *